Zu den Inhalten springen

Tumorzentrum Freiburg - CCCF

Prof. Dr. med. Gabriele Niedermann

Contact:

Center for Diagnostic and Therapeutic Radiology
Department of Radiation Oncology
Section of Molecular Radiation Oncology
Medical Center – University of Freiburg
Robert-Koch-Str. 3
D-79106 Freiburg
gabriele.niedermann@uniklinik-freiburg.de
http://www.uniklinik-freiburg.de/strahlenklinik.html

Current Positions:

Head of Section of Molecular Radiation Oncology, Department of Radiation Oncology, Medical Center - University of Freiburg

Research Focus:

Cancer stem cell research; charaterization of cancer stem cell radioresistance and identification of cancer stem cell radiosensitizers; non-invasive imaging of cancer stem cells; development of theranostic agents for the visualization and therapeutic eradication of cancer stem cells.

The role of immunology in radiotherapy, identification of optimal combinations of radio- and immunotherapy, immuno-imaging.

Research Website http://www.uniklinik-freiburg.de/strahlenklinik/forschung.html

DKTK Research Program:

Radiation Oncology & Imaging; Stem Cells and Oncology; Cancer Immunology and Immunotherapy

DKTK Research Topic:

Biological Individualization of Radiation Oncology
Radiation Biology

Working Group Members:

Dr. Hua Jing, Dr. Kevin Zhu, Jayashree Lahoti, Dept. of Radiation Oncology, University Freiburg Medical Center
Dr. Claudia Weidensteiner, Dept. of Radiology/Medical Physics, University Freiburg
Medical Center

DKTK Publications:

Popp I, Grosu AL, Niedermann G, Duda DG. Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. Radiotherapy and Oncology [Internet]. August 2016 [zitiert 18. August 2016]; Verfügbar unter: linkinghub.elsevier.com/retrieve/pii/S0167814016312051

Jing H, Weidensteiner C, Reichardt W, Gaedicke S, Zhu X, Grosu A-L, Kobayashi H, Niedermann G. Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies. Theranostics. 2016;6(6):862–74. 

Hettich M, Braun F, Bartholomä MD, Schirmbeck R, Niedermann G. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. Theranostics. 2016;6(10):1629–40.

Hettich M, Lahoti J, Prasad S, Niedermann G. Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing -Irradiation. Cancer Research. 15. August 2016;76(16):4673–83. 

Zhu X, Niedermann G. Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells. Oncoscience. 2015;2(5):476–82.

Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, Firat E, Klingner K, Schueler J, Wider D, Wasch RM, Herold-Mende C, Elsasser-Beile U, Niedermann G. Effective eradication of glioblastoma stem cells by local application of an AC133/CD133-specific T cell-engaging antibody and CD8 T cells. Cancer Research [Internet]. 3. April 2015 [zitiert 4. Mai 2015]; Verfügbar unter: cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-14-2415 

Zhu X, Prasad S, Gaedicke S, Hettich M, Firat E, Niedermann G. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget. 15. November 2014;

Gaedicke S, Braun F, Prasad S, Machein M, Firat E, Hettich M, Gudihal R, Zhu X, Klingner K., Schüler J., Herold-Mende C., Grosu AL., Behe M., Weber W., Mäcke H., Niedermann G. Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. Proceedings of the National Academy of Sciences. 2014;111(6):E692–E701.

Other:

Firat E, Weyerbrock A, Gaedicke S, Grosu AL, Niedermann G. Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote γ-irradiation-induced cell death in primary stem-like glioma cells. PLoS One. 2012;7(10):e47357. doi: 10.1371/journal.pone.0047357.

Bilger A, Bittner MI, Grosu AL, Wiedenmann N, Meyer PT, Firat E, Niedermann G, Weber WA, Milanović D. FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma : First tolerability and feasibility results. Strahlenther Onkol. 2014 Oct;190(10):957-961.

Kahlert UD, Maciaczyk D, Dai F, Claus R, Firat E, Doostkam S, Bogiel T, Carro  MS, Döbrössy M, Herold-Mende C, Niedermann G, Prinz M, Nikkhah G, Maciaczyk J. Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro. J Neuropathol Exp Neurol. 2012 Dec;71(12):1086-99.

Kahlert UD, Maciaczyk D, Doostkam S, Orr BA, Simons B, Bogiel T, Reithmeier T, Prinz M, Schubert J, Niedermann G, Brabletz T, Eberhart CG, Nikkhah G, Maciaczyk J. Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett. 2012 Dec 1;325(1):42-53.

Multhoff G, Gaipl US, Niedermann G. The role of radiotherapy in the induction of antitumor immune responses. Strahlenther Onkol. 2012 Nov;188 Suppl 3:312-5.

Site Coordinator Freiburg

Prof.Dr. Christoph Peters
Tumorzentrum Freiburg CCCF
Phone: +49-761-270-71500
Hugstetter Str. 55
79106 Freiburg

and

Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
Phone: +49-761-203-9600/9601
christoph.peters@mol-med.uni-freiburg.de​​    

Administrative Site Coordination

Dr. Anja Hernández
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
+49 (0)761 270 22810
anja.hernandez@dkfz-heidelberg.de